Jelinek Richard M 4
4 · Evolent Health, Inc. · Filed Jun 8, 2026
Research Summary
AI-generated summary of this filing
Evolent Health (EVH) Director Richard M. Jelinek Receives Award of 41,096 RSUs
What Happened
- Richard M. Jelinek, a director of Evolent Health, was granted 41,096 restricted stock units (RSUs) on June 4, 2026. The Form 4 reports an acquisition code "A" for an award, with a reported price of $0.00 (typical for equity awards; not a market purchase or sale).
Key Details
- Transaction date: 2026-06-04; Form 4 filed: 2026-06-08 (timely within SEC rules).
- Amount: 41,096 RSUs; reported acquisition price: $0.00; total reported value: $0.
- Shares owned after the transaction: not disclosed in the filing.
- Footnotes: (F1) Award granted under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. (F2) RSUs vest on the earlier of June 4, 2027 or the date of the Company's 2027 annual meeting, subject to continued service.
Context
- These RSUs are a form of equity compensation and will typically convert into common shares upon vesting (subject to the stated service condition). Grants like this reflect routine director compensation and are not the same as an open-market purchase or sale.
Insider Transaction Report
Form 4
Jelinek Richard M
Director
Transactions
- Award
Class A Common Stock
[F1][F2]2026-06-04+41,096→ 77,533 total
Holdings
- 15,000(indirect: By Trust)
Class A Common Stock
- 15,000(indirect: By the Richard M Jelinek GST)
Class A Common Stock
Footnotes (2)
- [F1]Represents restricted stock units granted to Mr. Jelinek pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
- [F2]Securities vest on the earlier of June 4, 2027, and the date of the Company's 2027 annual meeting, subject to the reporting person's continued service on the vesting date.
Signature
/s/ Jonathan Weinberg, Attorney-in-fact|2026-06-08